Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. - Issa,JP.; Garcia-Manero,G.; Giles,FJ. (Blood, 2004)